ECSP14013307A - Genzyme corporation - Google Patents

Genzyme corporation

Info

Publication number
ECSP14013307A
ECSP14013307A ECSP14013307A ECSP14013307A EC SP14013307 A ECSP14013307 A EC SP14013307A EC SP14013307 A ECSP14013307 A EC SP14013307A EC SP14013307 A ECSP14013307 A EC SP14013307A
Authority
EC
Ecuador
Prior art keywords
genzyme corporation
bma031
tcr
binds
complex
Prior art date
Application number
Other languages
English (en)
Inventor
Andreas Menrad
Clark Pan
Daniel Snell
Gina Lacorcia
Shrinivas Shankara
Huawei Qiu
Benjamin Kebble
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of ECSP14013307A publication Critical patent/ECSP14013307A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refierea un anticuerpomonoclonal que comprende CDRs de anticuerpo de múridos BMA031, el cual se une al complejo ??TCR.CD3 y posee propiedades biológicas mejoradas.
ECSP14013307 2011-09-12 2014-04-11 Genzyme corporation ECSP14013307A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161533510P 2011-09-12 2011-09-12

Publications (1)

Publication Number Publication Date
ECSP14013307A true ECSP14013307A (es) 2015-04-30

Family

ID=46851393

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013307 ECSP14013307A (es) 2011-09-12 2014-04-11 Genzyme corporation

Country Status (34)

Country Link
US (3) US10017573B2 (es)
EP (1) EP2755999B1 (es)
JP (2) JP6096196B2 (es)
KR (1) KR20140072092A (es)
CN (3) CN119119269A (es)
AU (2) AU2012307816C1 (es)
BR (2) BR122021001193B1 (es)
CA (1) CA2847949C (es)
CL (2) CL2014000574A1 (es)
CO (1) CO6930307A2 (es)
CR (1) CR20140127A (es)
DK (1) DK2755999T3 (es)
DO (1) DOP2014000052A (es)
EC (1) ECSP14013307A (es)
ES (1) ES2667893T3 (es)
GT (1) GT201400045A (es)
HU (1) HUE037470T2 (es)
IL (2) IL231304B (es)
LT (1) LT2755999T (es)
MA (1) MA35711B1 (es)
MX (2) MX379660B (es)
MY (1) MY173924A (es)
NI (1) NI201400019A (es)
PE (1) PE20141548A1 (es)
PH (1) PH12014500408A1 (es)
PL (1) PL2755999T3 (es)
PT (1) PT2755999T (es)
RU (2) RU2017129721A (es)
SG (2) SG11201400126PA (es)
TN (1) TN2014000107A1 (es)
TW (1) TWI593706B (es)
UA (1) UA115533C2 (es)
UY (1) UY34317A (es)
WO (1) WO2013037484A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
SI2895513T1 (sl) * 2012-09-12 2018-11-30 Genzyme Corporation Polipeptidi, ki vsebujejo FC, s spremenjeno glikozilacijo in zmanjšano efektorsko funkcijo
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
IL289918B2 (en) 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
MX384246B (es) * 2013-10-30 2025-03-14 Genzyme Corp POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.
US10995148B2 (en) 2014-03-19 2021-05-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
PT3204425T (pt) 2014-10-09 2020-12-18 Genzyme Corp Conjugados anticorpo fármaco glicomanipulados
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
MX2017015619A (es) * 2015-06-01 2018-08-15 Medigene Immunotherapies Gmbh Anticuerpos especificos de receptor de celulas t.
WO2017070608A1 (en) * 2015-10-23 2017-04-27 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
RU2708558C1 (ru) * 2018-12-13 2019-12-09 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
WO2021136415A1 (zh) * 2019-12-30 2021-07-08 博雅辑因（北京）生物科技有限公司 一种纯化ucart细胞的方法与应用
CN113122504A (zh) * 2019-12-30 2021-07-16 博雅辑因（北京）生物科技有限公司 一种纯化ucart细胞的方法与应用
CN113122503B (zh) * 2019-12-30 2022-10-11 博雅缉因（北京）生物科技有限公司 一种靶向t细胞淋巴瘤细胞的通用型car-t及其制备方法和应用
EP4084823A4 (en) * 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
CN113088495B (zh) * 2020-01-09 2024-08-16 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN119233999A (zh) * 2022-05-25 2024-12-31 羿尊生物医药（浙江）有限公司 靶向细胞膜受体蛋白的融合蛋白及其应用

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5149782A (en) 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
DE68928427T2 (de) 1988-09-15 1998-06-04 Univ Columbia Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5792456A (en) 1994-08-04 1998-08-11 Bristol-Myers Squibb Company Mutant BR96 antibodies reactive with human carcinomas
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
WO1998005787A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
AU6059699A (en) 1998-09-23 2000-04-10 Regents Of The University Of California, The Synthetic peptides, conjugation reagents and methods
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
CN1110322C (zh) 1999-07-21 2003-06-04 中国医学科学院医药生物技术研究所 单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EA008831B1 (ru) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
RU2392324C2 (ru) * 2003-09-18 2010-06-20 Симфоген А/С Способ связывания интересующих последовательностей
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US7001978B2 (en) 2003-11-19 2006-02-21 Xerox Corporation Unsaturated ester substituted polymers with reduced halogen content
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP1745141B2 (en) 2004-05-04 2019-09-25 Novo Nordisk Health Care AG O-linked glycoforms of faktor vii and method to manufacture them
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
CA2581505A1 (en) 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JP4829609B2 (ja) * 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
EP1907001B1 (en) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
JP2009504569A (ja) 2005-06-30 2009-02-05 セントカー・インコーポレーテツド 向上した治療活性をもつ方法および組成物
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CZ2005627A3 (cs) 2005-10-03 2006-09-13 Flek@Jaroslav Zubní kartácek
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CA2655903A1 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
FI20060946A0 (fi) 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
CA2666308C (en) 2006-10-26 2014-09-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
ES2464815T3 (es) * 2007-01-09 2014-06-04 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
WO2008091954A2 (en) 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
WO2009045894A1 (en) 2007-09-28 2009-04-09 Centocor, Inc. Methods and structural conformations of antibody preparations with increased resistance to proteases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2698541C (en) 2007-10-19 2018-01-09 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
WO2009089396A2 (en) 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugation of polypeptides using oligosaccharyltransferases
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
EP2811017A2 (en) 2008-04-21 2014-12-10 Novo Nordisk Health Care AG Hyperglycosylated human coagulation factor IX
UA40611U (ru) 2008-05-26 2009-04-27 Владимир Семенович Живченко Способ десульфурации железоуглеродистого расплава в тигельной печи
WO2010027797A1 (en) 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
DK2542256T3 (da) * 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
BR112013003095B1 (pt) 2010-08-10 2023-03-28 Glycotope Gmbh Método para controle da meia-vida em circulação de um anticorpo ou um fragmento ou derivado funcional do mesmo, composições de anticorpo, seu usos e seus métodos de produção
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
CN107088225A (zh) 2011-03-11 2017-08-25 阿米库斯治疗学公司 治疗法布里病的给药方案
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
SI2895513T1 (sl) 2012-09-12 2018-11-30 Genzyme Corporation Polipeptidi, ki vsebujejo FC, s spremenjeno glikozilacijo in zmanjšano efektorsko funkcijo
IL289918B2 (en) 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
US10995148B2 (en) 2014-03-19 2021-05-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
WO2015157446A1 (en) 2014-04-08 2015-10-15 University Of Georgia Research Foundation Inc. Site-specific antibody-drug glycoconjugates and methods
PT3204425T (pt) 2014-10-09 2020-12-18 Genzyme Corp Conjugados anticorpo fármaco glicomanipulados
US10280317B2 (en) 2016-07-07 2019-05-07 Northwestern University Enhanced conductivity, adhesion and environmental stability of printed graphene inks with nitrocellulose

Also Published As

Publication number Publication date
PE20141548A1 (es) 2014-11-18
AU2012307816C1 (en) 2017-12-07
MA35711B1 (fr) 2014-12-01
MX2014002963A (es) 2015-03-19
CN104684930A (zh) 2015-06-03
TWI593706B (zh) 2017-08-01
GT201400045A (es) 2015-07-29
NZ717726A (en) 2017-11-24
WO2013037484A2 (en) 2013-03-21
AU2012307816A1 (en) 2014-04-24
DK2755999T3 (en) 2018-05-22
IL231304A0 (en) 2014-04-30
TN2014000107A1 (en) 2015-07-01
WO2013037484A8 (en) 2014-05-22
CN110272492A (zh) 2019-09-24
EP2755999B1 (en) 2018-01-31
IL231304B (en) 2018-06-28
PT2755999T (pt) 2018-05-14
CR20140127A (es) 2014-08-20
UA115533C2 (uk) 2017-11-27
RU2630656C2 (ru) 2017-09-11
BR122021001193B1 (pt) 2023-05-16
CA2847949C (en) 2019-12-03
RU2017129721A3 (es) 2019-02-06
ES2667893T3 (es) 2018-05-14
JP2017108752A (ja) 2017-06-22
WO2013037484A3 (en) 2013-08-29
CN104684930B (zh) 2019-04-26
LT2755999T (lt) 2018-05-10
US10017573B2 (en) 2018-07-10
US20150099861A1 (en) 2015-04-09
KR20140072092A (ko) 2014-06-12
MX355735B (es) 2018-04-27
CO6930307A2 (es) 2014-04-28
EP2755999A2 (en) 2014-07-23
PH12014500408A1 (en) 2022-04-18
DOP2014000052A (es) 2014-09-15
US20180237522A1 (en) 2018-08-23
AU2012307816A8 (en) 2014-06-19
NI201400019A (es) 2014-10-10
JP6096196B2 (ja) 2017-03-15
RU2014114527A (ru) 2015-10-20
CA2847949A1 (en) 2013-03-21
AU2017261557A1 (en) 2017-12-07
HUE037470T2 (hu) 2018-08-28
HK1199268A1 (en) 2015-08-07
IL259826A (en) 2018-07-31
MY173924A (en) 2020-02-27
US11186638B2 (en) 2021-11-30
CL2014000574A1 (es) 2015-04-10
MX379660B (es) 2025-03-11
SG11201400126PA (en) 2014-03-28
JP6599911B2 (ja) 2019-10-30
BR112014005644A2 (pt) 2017-03-28
JP2014527802A (ja) 2014-10-23
CN119119269A (zh) 2024-12-13
UY34317A (es) 2013-02-28
TW201313741A (zh) 2013-04-01
RU2017129721A (ru) 2019-02-06
AU2017261557B2 (en) 2019-11-14
AU2012307816B2 (en) 2017-08-17
CL2017001730A1 (es) 2018-03-16
PL2755999T3 (pl) 2018-09-28
NZ623656A (en) 2016-04-29
US20220153841A1 (en) 2022-05-19
SG10201601738UA (en) 2016-04-28

Similar Documents

Publication Publication Date Title
ECSP14013307A (es) Genzyme corporation
CO7111294A2 (es) Anticuerpo anti-fgfr2
MX373426B (es) Moleculas de enlace a il-18.
PE20221007A1 (es) Anticuerpos anti-receptor de transferrina con afinidad disenada
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
MX2019001355A (es) Anticuerpos monoclonales multiespecíficos.
CR20110559A (es) Anticuerpos específicos para cadherina-17
MX2017015042A (es) Anticuerpos cd123 y conjugados de los mismos.
CO6781491A2 (es) Anticuerpos del cea
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
PL2552955T3 (pl) Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klirens antygenu
CR20120127A (es) Anticuerpos monoclonales
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
MX2016008187A (es) Anticuerpos biespecificos anti-hapteno/anti-receptor de barrera hematoencefalica, complejos de los mismos y su uso como transportadores a traves de la barrera hematoencefalica.
MX2015004449A (es) Conjugados del anticuerpo pirrolobenzodiazepina.
EA201792055A1 (ru) Антитела против cd48 и их конъюгаты
JO3625B1 (ar) بروتينات رابطة للأنتيجين cd27l
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
HK1206283A1 (en) Treatment of multiple sclerosis with anti-cd19 antibody
CR20120553A (es) Anticuerpos il-25 humanizados
BR112015021964A2 (pt) Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos
HK1219485A1 (zh) 用於cdr移植的受体框架
NZ737925A (en) Monoclonal antibodies against c-met